FHI:NYSEFederated Hermes, Inc. Analysis
Data as of 2026-05-19 - not real-time
$54.69
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Federated Hermes posted a 13.1% year‑over‑year revenue increase to $479 million and a GAAP EPS of $5.15, comfortably beating consensus estimates, while maintaining a robust gross margin of 68% and an ROE of 33.8%. Its valuation appears attractive – a trailing P/E of 10.6 versus an industry average of 16.6 and a dividend yield of 2.57% backed by a modest 26% payout ratio, indicating sustainable cash flow. However, the stock is trading below its 20‑day (55.67) and 50‑day (56.32) SMAs, with a bearish MACD crossover and decreasing volume, suggesting short‑term pressure near the $52.35 support level.
The company’s balance sheet is solid, with cash exceeding debt and free cash flow of $364 million, while the strategic push on assets under management and recent executive appointment support a medium‑term upside toward the $58.39 resistance. Given the neutral market trend, moderate beta (≈0.8) and 30‑day volatility of 33%, the risk profile is balanced, making a hold for the near term and a buy for medium to long horizons appropriate.
The company’s balance sheet is solid, with cash exceeding debt and free cash flow of $364 million, while the strategic push on assets under management and recent executive appointment support a medium‑term upside toward the $58.39 resistance. Given the neutral market trend, moderate beta (≈0.8) and 30‑day volatility of 33%, the risk profile is balanced, making a hold for the near term and a buy for medium to long horizons appropriate.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below short‑term moving averages
- Proximity to technical support at $52.35
- Attractive dividend yield providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 13% revenue growth and record AUM
- Undervalued relative to industry peers (P/E 10.6 vs 16.6)
- Potential upside to resistance around $58.40
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong ROE (33.8%) and consistent free cash flow
- Sustainable dividend with low payout ratio
- Strategic leadership additions and continued asset management positioning
Key Metrics & Analysis
Financial Health
Revenue Growth13.10%
Profit Margin21.47%
P/E Ratio10.6
ROE33.76%
ROA15.33%
Debt/Equity35.67
P/B Ratio3.3
Op. Cash Flow$311.9M
Free Cash Flow$364.8M
Industry P/E16.6
Technical Analysis
TrendNeutral
RSI44.9
Support$52.35
Resistance$58.39
MA 20$55.67
MA 50$56.32
MA 200$53.31
MACDBearish
VolumeDecreasing
Fear & Greed Index89.38
Valuation
Fair Value$110.34
Target Price$55.43
Upside/Downside1.35%
GradeUndervalued
TypeBlend
Dividend Yield2.57%
Risk Assessment
Beta0.80
Volatility33.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.